Preprint Case Report Version 1 This version is not peer-reviewed

Eczematous Adverse Drug Reaction after Selpercatinib Treatment: Case Report

Version 1 : Received: 26 September 2024 / Approved: 26 September 2024 / Online: 26 September 2024 (16:44:59 CEST)

How to cite: Li, B.; Cao, P.; Xu, W.; Zhang, L. Eczematous Adverse Drug Reaction after Selpercatinib Treatment: Case Report. Preprints 2024, 2024092145. https://doi.org/10.20944/preprints202409.2145.v1 Li, B.; Cao, P.; Xu, W.; Zhang, L. Eczematous Adverse Drug Reaction after Selpercatinib Treatment: Case Report. Preprints 2024, 2024092145. https://doi.org/10.20944/preprints202409.2145.v1

Abstract

This study reports a 50-year-old patient presented with eczematous drug-eruption induced by selpercatinib after the treatment of non-small cell lung cancer (NSCLC). The patient has symmetric erythematous papules and plaques all over the body with dry, scaly skin accompanied by severe pruritus and visible scarring. After systemic treatment with glucocorticoids, the skin lesions of the patient were well reduced. Currently, the medical literature on the incidence of selpercatinib-induced cutaneous eczematous reactions and their clinical management is scarce. Therefore, this study provides novel evidence for the treatment of selpercatinib-induced cutaneous eczematous reactions.

Keywords

eczematous reaction; adverse drug reaction; selective RET inhibitor; Selpercatinib; glucocorticoid

Subject

Medicine and Pharmacology, Dermatology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.